In a significant move for the oncology field, ARTBIO, Inc. has entered into a groundbreaking partnership with 3B Pharmaceuticals GmbH that aims to advance a novel alpha radioligand therapy for treating solid tumors. ARTBIO, known for its innovative AlphaDirect™ platform, focuses on 212Pb-based a
November 14, 2024In a recent pivotal study published in Nature Communications, scientists have made significant strides in understanding the genetic underpinnings of testicular cancer, offering profound insights into its development and unveiling potential treatment strategies. This comprehensive research aims to
November 14, 2024The advent of MRI-guided stereotactic body radiotherapy (SBRT) represents a significant advancement in the treatment of prostate cancer, offering improved precision and reduced long-term side effects compared to conventional CT-guided approaches. This breakthrough is underscored by findings from a
November 14, 2024The rise of artificial intelligence (A.I.) in the pharmaceutical industry signifies a transformative period, placing unprecedented power in the hands of tech-driven drug discovery and igniting debates about innovation, control, and patient safety. Subject to regulatory scrutiny, the FDA has
November 13, 2024In the world of modern medicine, finding innovative, safer, and more effective treatments for cancer remains a relentless pursuit. Researchers from the University of Nottingham have turned their attention to an unassuming yet potent ally in this fight—the parasitic fungus Cordyceps militaris. S
November 13, 2024Cancer research has entered a new era with the advent of patient-derived organoids (PDOs). These sophisticated three-dimensional (3D) models, grown from patient cells, have revolutionized our understanding of tumors and their microenvironments. By mimicking the complexity of human tumors, PDOs have
November 13, 2024